NEW YORK (GenomeWeb News) – Life Technologies today announced a worldwide, non-exclusive deal with iPS Academia Japan for its induced pluripotent stem cell patent portfolio.

The agreement grants Life Tech the rights to commercialize a range of products and services designed to create iPS cells and differentiate them into any cell type for drug discovery and pre-clinical research. Life Tech will also be able to provide iPS cell creation, differentiation, and screening services to the scientific community.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.